Anabolic / androgenic steroids cause a very negative femara side effects attitude in the public and in the media. Along with ethical and moral accusations against them, many terrible side effects are attributed to them.
Unfortunately femara side effects, the mass media, because of the direction of their actions, give a sensation of a significant amount of false information.
In the course of the anti-steroid company, examples are given of cases of diseases reported to the scientific literature, to which steroids lead, and do so with the aim of intimidating and cautioning, in order to show what fate awaits those who take these medicines.
What is held back here for propaganda purposes is that in these cases it is a question of patients who, prior to steroid therapy, suffered significant health disorders, in part even with terrible violations.
In fact, steroids are dispensed only by prescription, in addition, they are femara side effects drugs, medications that affect various psychological processes, and, therefore, have potential side effects.
When determining the “side effects”, it is necessary to distinguish between toxic and hormonal-related side effects. This important division is omitted by the official party in part from pure ignorance, and most often deliberately, because The only way to spread incredible sensational facts and false information.
To the category of toxic side effects of anabolic / androgenic steroids are potential effects on the liver. They can be expressed in a variety of violations of the liver.
In the literature, cases are known where the onset of holostases (bile stasis in the liver), hepatosis peliosis femara side effects (blood-filled caverns of liver tissue, cysts) and liver carcinomas were associated with the use of anabolic / androgenic steroids. And yet, it is important that these forms of manifestation were encountered exclusively only in patients who used long-acting steroid therapy and already had significant liver function abnormalities, as well as other serious diseases of internal organs, before the first steroids were taken.
It further strikes that at the same time the steroid therapy that was taken consisted of almost exclusively 17-alpha, oral androgenic steroids. During therapy for several years, potentially toxic liver chemicals Methyltestosterone and Oxandrolone were taken without interruption. Indication that steroids cause similar side effects in healthy athletes could be taken into account only in very few cases that do not have statistical confirmation and do not give any conclusions regarding the expected damage to the liver when taking a / a steroids .
“As soon as a parallel is made between the use of steroids and tumor diseases, there is not a single report where testosterone or testosterone ester is responsible for liver carcinoma.
The cause was always androgens / anabolics with a 17-alpha component of the steroid molecule … And testosterone and its ethers seem to be nontoxic (or low-toxic) for the liver femara side effects … Toxic liver damage: as stated above, they should be expected only from the calcified For 17-alpha options … With the right choice of the drug there is no danger. Time to emphasize that almost all liver damage has been registered in people who received a doctor’s order to take steroids for the treatment of pre-existing, serious diseases.
Although possible damage to the liver and delayed damage that may appear may be decades later not excluded, empirical evidence Show that, despite the frequent, prolonged use of potentially toxic liver toxics, accrued for 17-alpha steroids by athletes, the manifestation of these lesions is rare.
In healthy postmenopausal women, a single dose of lemon 0.5 mg and 2.5 mg reduces the level of estrone and estradiol in serum (relative to the baseline level) by 75-78% and by 78%, respectively. The maximum reduction is achieved in 48-78 hours.
In women with a common form of postmenopausal breast cancer, the daily use of letrozole at a dose of 0.1 mg to 5 mg reduces estradiol, estrone and estrone sulfate levels in blood plasma by 75-95% of the baseline in all patients who receive treatment. When using the drug at a dose of 0.5 mg or more, in many cases the concentrations of estrone and estrone sulfate are below the sensitivity limit of the hormone determination method used. This indicates that with the help of these doses of the drug, a more pronounced suppression of the synthesis of estrogens is achieved. Suppression of estrogens was maintained throughout treatment in all patients.
Letrozole is a highly specific inhibitor of aromatase activity. There were no violations of the synthesis of steroid hormones in the adrenal glands. Postmenopausal patients treated with letrozole at a daily dose of 0.1 to 5 mg showed no clinically significant changes in blood plasma concentrations of cortisol, aldosterone, 11 deoxycortisol, 17-hydroxyprogesterone, ACTH, or renin activity. The ACTH stimulation test at 6 and 12 weeks of therapy with letrozole at a daily dose of 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 2.5 mg, and 5 mg showed no noticeable decrease in the synthesis of aldosterone or cortisol . Thus, there is no need to additionally prescribe glucocorticoids and mineralocorticoids.
In healthy postmenopausal women, after single application of letrozole at doses of 0.1 mg, 0.5 mg and 2.5 mg, the changes in the androgen concentration (androstenedione and testosterone) in the blood plasma were not detected. In postmenopausal women who received letrozole at a daily dose of 0.1 mg to 5 mg, there was also no change in the level of androstenedione in the blood plasma. All this indicates that the blockade of the biosynthesis of estrogens does not lead to the accumulation of androgens, which are precursors of estrogens. In patients receiving letrozole, no changes in the concentrations of luteinizing and follicle-stimulating hormones in the blood plasma were noted, nor were changes in the thyroid function assessed by thyrotropic hormone, T4 and T3 levels.